Torticollis

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Retrieved on: 
Thursday, May 9, 2024
Biotechnology, General Health, Pharmaceutical, Health, Spasticity, Pain, FDA, Patient, CMS, Headache, Label, Death, Speech, ASPEN, Dysphagia, Therapy, Torticollis, Physician, Hubli railway division, Neurology, Medicare, Neurotoxin, MBA, Injection, Pharmaceutical industry

The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.

Key Points: 
  • The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.
  • “DAXXIFY provides a significant opportunity for Revance and marks the culmination of our decades-long mission to bring true innovation to the therapeutics market.
  • Following the FDA’s approval of DAXXIFY for cervical dystonia in August 2023, Revance launched the DAXXIFY cervical dystonia PrevU early experience program with the objective of optimizing treatment outcomes for patients and ensuring smooth practice integration.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Retrieved on: 
Thursday, May 9, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Quarter, GAAP, Investment, Research, Depreciation, Yoy, Traction, Webcast, Growth, Therapy, RHA, Physiology, Torticollis, Medicare, Marketing, Collection, Bank statement, Adjustment, Clinical trial, ID, Government, Lip, Pharmaceutical industry

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points: 
  • Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
  • Research and development (R&D) expenses for the first quarter ended March 31, 2024 were $14.4 million compared to $17.5 million for the same period in 2023.
  • Total operating expenses for the first quarter ended March 31, 2024 were $98.8 million compared to $92.5 million for the same period in 2023.
  • ET on May 9, 2024 to discuss its financial results and provide a corporate update.

AEON Biopharma Provides Update on Development Pipeline

Retrieved on: 
Thursday, May 9, 2024
AEON, FDA, Post-traumatic stress disorder, Safety, SGB, Conference, Gastroparesis, Lidocaine, Migraine, IND, Patent, Patient, Torticollis, Toxicity, Pharmaceutical industry

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications.
  • Several of these programs are ready to advance into the next stage of clinical development.
  • When taking into consideration our clinical pipeline and combining it with our differentiated business model, we see a number of compelling opportunities to pursue,” said Marc Forth, President and Chief Executive Officer of AEON.
  • Post-Traumatic Stress Disorder (PTSD) - IND-enabling studies are already planned, which are designed to support the development of ABP-450 in PTSD.

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, April 12, 2024
Research, Neurology, Clinical Trials, Health Insurance, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, FDA, University, Torticollis, Headache, DSM-IV codes, Safety, American Academy of Neurology, MD, University of South Florida, ASPEN, Patient, AAN, Physician, Neuron, MBA, Therapy, Pharmaceutical industry

Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.

Key Points: 
  • Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced two poster presentations on DAXXIFY® for the treatment of cervical dystonia at the annual meeting of American Academy of Neurology (AAN), taking place April 13-18, 2024, in Denver, Colorado.
  • In the ASPEN-OLS 52-week long-term follow-up study, approximately 60% of retreatments were at 16 weeks or later.
  • Additionally, the studies show that adverse event rates remained low across all retreatment scenarios.
  • A second poster, by Dr. Han Lee and colleagues, examines DAXXIFY’s novel formulation and the role of Revance’s custom-engineered peptide (RTP004), in clinical performance.

Plagiocephaly and Torticollis Awareness Month

Retrieved on: 
Wednesday, March 27, 2024
Parent, Osteopathy, SAN, Colic, Plagiocephaly, Torticollis, FAAP, OMT

SAN DIEGO, March 27, 2024 /PRNewswire/ -- The Osteopathic Center for Children & Osteopathy's Promise to Children is now looking for infants 4 months old and younger diagnosed with plagiocephaly (flat head syndrome), which affects 47% of infants in the US. If left untreated, this can cause vision problems, muscular tightness, dental issues, & developmental delays. Qualified infants who enroll in this study will receive gentle, hands-on treatment known as Osteopathic Manipulative Treatment (OMT), which has been proven to address the underlying cause of plagiocephaly, reducing its impact on the child's development more than current treatments, such as helmet therapy.

Key Points: 
  • New Study Offering Free Plagiocephaly Treatment (an alternative to helmet therapy) in San Diego, California!
  • SAN DIEGO, March 27, 2024 /PRNewswire/ -- The Osteopathic Center for Children & Osteopathy's Promise to Children is now looking for infants 4 months old and younger diagnosed with plagiocephaly (flat head syndrome), which affects 47% of infants in the US .
  • If left untreated, this can cause vision problems, muscular tightness, dental issues, & developmental delays.
  • "We use OMT to evaluate & treat the whole body, not just one area of concern.

Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, General Health, Pharmaceutical, Health, Therapy, RHA, Research, CMS, Fosun International, Education, MD, Investment, Physician, FDA, Marketing, Food, Growth, MBA, Adjustment, Collection, GAAP, Medicare, Webcast, Depreciation, Patient, Tax, OPEX, ASPEN, Lip, Torticollis, Ageing, American Academy, Pharmaceutical industry

Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • Excluding depreciation, amortization, stock-based compensation and restructuring charges, non-GAAP R&D expenses were $18.6 million and $65.5 million, respectively, for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter and full year 2023 RHA Collection revenue of $34.5 million and $128.6 million, respectively.
  • ET on February 28, 2024, to discuss its financial results and provide a corporate update.

Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®

Retrieved on: 
Friday, February 2, 2024
Neurology, FDA, Public Relations, Investor Relations, Clinical Trials, Communications, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Injection, Spasticity, Government, Therapy, Patient, Safety, Incidence, Torticollis, American Academy, Neurotoxin, Speech, ASPEN, Food, Physician, Total, Muscle weakness, CMS, Death, MHSA, Food and Drug Administration, Hubli railway division, Dysphagia, Pharmaceutical industry

The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.

Key Points: 
  • The company also announced today the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, the medical journal of the American Academy of Neurology.
  • “Importantly, the real-world clinical results of DAXXIFY from the patients I have injected so far in PrevU, including safety, efficacy and duration, are in-line with those seen in the ASPEN-1 study.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
  • To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669.

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Retrieved on: 
Thursday, January 18, 2024
AEON, Clavicle, Patient, Heart rate, Research, PTSD, Post-traumatic stress disorder, AB toxin, Stellate ganglion, OLE, Neck, DSM-IV codes, Torticollis, Safety, INA, DBP, Head, Botulinum toxin, Lidocaine, IND, Ptosis, FDA, Toxicity, Rat, SGB, Acute stress disorder, Data, Week, Anatomy, Pharmaceutical industry

IRVINE, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today presented new clinical and pre-clinical data for ABP-450 in treating cervical dystonia (CD) and posttraumatic stress disorder (PTSD) at TOXINS 2024, a leading conference held by the International Neurotoxin Association (INA) from January 17th - 20th at the Estrel Berlin in Berlin, Germany.

Key Points: 
  • ABP-450 did not appear to increase treatment-related TEAEs at any dose in the study.
  • These results support further investigation of ABP-450 as a treatment option for patients with CD and other movement disorders.
  • “We are excited to announce positive data from the 52-week OLE portion of the Phase 2 study of ABP-450 for CD.
  • The posters presented by AEON at the TOXINS 2024 conference can be accessed on the Events and Presentations page of the Company’s corporate website.

Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

Retrieved on: 
Monday, January 8, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Patient, Fosun International, RHA, Collection, Dysphagia, Neurotoxin, FDA, Hubli railway division, Ageing, Torticollis, Therapy, Education, Death, Speech, COVID-19, Adjustment, Spasticity, Growth, Investment, Lip, Finance, PMA, GAAP, Hyaluronic acid

Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.

Key Points: 
  • Revance Therapeutics , Inc. (NASDAQ:RVNC) today provided a corporate update as well as preliminary unaudited fourth quarter and full year 2023 financial results, 2024 guidance and financial outlook.
  • We wish Dustin the best in his new endeavors.”
    Corporate Updates and Preliminary Q4 and FY 2023 Financial Results:
    Revance expects Q4 2023 preliminary unaudited DAXXIFY revenue to be between $23.5 million and $24.5 million.
  • Full year 2023 preliminary unaudited DAXXIFY revenue is expected to be between $83.5 million and $84.5 million.
  • Revance expects preliminary unaudited fourth quarter 2023 RHA Collection revenue to be between $34 million and $35 million, and full year preliminary unaudited 2023 RHA Collection revenue to be between $128 million and $129 million.

AEON Biopharma Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
AEON, Steps, Migraine, AB toxin, Acquisition, Safety, NYSE, Food, Investment, Common stock, Patient, FDA, NYSE American, Patent, Phase II, Funding, Use, Torticollis, MMD, Pharmaceutical industry, Security (finance)

IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the third quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • – Ongoing Phase 2 trial for the preventive treatment of chronic migraine has enrolled over 430 subjects; anticipate completing enrollment in Q4 2023 and announcing topline data in 2H 2024 –
    IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, announced financial results for the third quarter ended September 30, 2023 and provided a business update.
  • These data are expected to further support advancing our chronic and episodic migraine programs into pivotal clinical trials.
  • In addition, we continue to evaluate multiple parameters for the planned Phase 3 trial of ABP-450 for the preventive treatment of episodic migraine.
  • Cash, Cash Equivalents and Investments – The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.